Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
207.91
+2.36 (1.15%)
Market open: Aug 12, 2026, 10:08 AM EDT
205.70
+0.15 (0.07%)
Previous after-hours: Aug 11, 2026, 7:58 PM EDT
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Name | Position |
|---|---|
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor |
| Mr. Jack Anders | Chief Financial Officer |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Walter Reiher Ph.D. | Chief Information Officer |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-05 | 8-K | rvmd-20260805.htm |
| 2026-06-22 | 8-K | d123125d8k.htm |
| 2026-05-06 | 8-K | rvmd-20260506.htm |
| 2026-05-06 | 10-Q | rvmd-20260331.htm |
| 2026-04-28 | DEFA14A | d12857ddefa14a.htm |
| 2026-04-27 | DEF 14A | d111313ddef14a.htm |
| 2026-04-17 | 8-K | d19920d8k.htm |
| 2026-04-16 | 8-K | d95226d8k.htm |
| 2026-04-15 | 305B2 | d138323d305b2.htm |
| 2026-04-13 | 8-K | d69348d8k.htm |